World News: 11:00 GMT Friday 12th July 2019. [Genmab A/S via Globe Newswire via SPi World News]
“With this agreement the scope of product concepts under development at Genmab has been expanded. CD47 has shown potential as a target for cancer and we believe that a bispecific approach may open up potential for differentiated therapies. We are always looking to use our in-house expertise in novel ways; we look forward to seeing the results from the combination of Genmab’s DuoBody technology with a CD47 antibody from BliNK Biomedical,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
BliNK Biomedical is a privately-owned biopharmaceutical company based in Marseille, France, focused on discovery and development of therapeutic antibodies in oncology and immuno-oncology.
Media Release no. 08CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
Globe Newswire: 11:00 GMT Friday 12th July 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.